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Brain edema and swelling is a critical factor in the high mortality and morbidity associated with
traumatic brain injury (TBI). Despite this, the mechanisms associated with its development are
poorly understood and interventions have not changed in over 30 years. Although neuropeptides
and neurogenic inflammation have been implicated in peripheral edema formation, their role in the
development of central nervous system edema after brain trauma has not been investigated. This
study examines the role of the neuropeptide, substance P (SP), in the development of edema and
functional deficits after brain trauma in rats. After severe diffuse TBI in adult male rats, neuronal and
perivascular SP immunoreactivity were increased markedly. Perivascular SP colocalized with
exogenously administered Evans blue, supporting a role for SP in vascular permeability. Inhibition
of SP action by administration of the neurokinin-1 (NK1) antagonist, N-acetyl-L-tryptophan, at
30 mins after trauma attenuated vascular permeability and edema formation. Administration of the
NK1 antagonist also improved both motor and cognitive neurologic outcomes. These findings
suggest that SP release is integrally linked to the increased vascular permeability and edema
formation after brain trauma, and that treatment with an NK1 receptor antagonist reduces edema and
improves neurologic outcome.
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Introduction
Traumatic brain injury (TBI) is the leading cause of
death and disability in people under 40 years of age
with the global cost for rehabilitation and care of
these individuals exceeding US$50 billion per year
(Jacobs et al, 2000). Despite the enormity of this
public health problem, no effective treatment cur-
rently exists.
It is now accepted that TBI results in the develop-
ment of neurologic deficits through two main
mechanisms (McIntosh et al, 1996). The first is
primary injury, which occurs at the time of the
trauma and includes mechanical processes, such as
shearing, laceration, and stretching of nerve fibers.
Secondary injury occurs at later time points, and is
composed of biochemical and physiologic factors
that are initiated by the primary event and manifest
over time. It has been shown earlier that much of the
morbidity after brain injury is associated with the
development of this secondary injury cascade
(McIntosh et al, 1996). A number of secondary injury
factors have been identified, including blood–brain
barrier (BBB) opening, edema formation, release of
excitatory amino acids, ion changes, oxidative stress,
and bioenergetic failure, among others. Of the
secondary injury factors, the formation of edema
has long been known to be critical to outcome after
injury (Lobato et al, 1988; Sarabia et al, 1988).
Although the mechanisms associated with the
formation of edema are still unclear, studies of
peripheral tissue edema (Woie et al, 1993) have
shown an association between neuropeptides and
the development of increased vascular permeability
and edema; this event has been termed ‘neurogenic
inflammation.’
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Neurogenic inflammation is a neurally elicited
reaction that has typical characteristics of an inflam-
matory reaction, including vasodilation, protein
extravasation, and tissue swelling. Studies of per-
ipheral nerves have shown that neurogenic inflam-
mation is the result of stimulation of C-fibers, which
causes the release of neuropeptides, including sub-
stance P (SP), calcitonin gene-related peptide , and
neurokinin A (NKA). Although all three neuropep-
tides are involved in the process, it is SP that has
been generally accepted to be associated with
increased microvascular permeability and edema
formation (Newbold and Brain, 1995). Edema forma-
tion in the brain, when left uncontrolled, results in
an increase in intracranial pressure that may lead to a
decrease in brain tissue perfusion, localized hypoxia
and ischemia, and even tissue herniation and death.
Therefore, it is of particular interest to attenuate or
inhibit such inflammation after TBI. Although a
number of studies have investigated the role of
classic inflammation in edema formation after TBI
(Lenzlinger et al, 1997; Stahel et al, 1998), only one
study has examined the role of neurogenic inflam-
mation in this process. Nimmo et al (2004) showed
that neuropeptide depletion with preinjury capsai-
cin administration significantly attenuated the BBB
opening, edema formation, and the development of
both motor and cognitive deficits. Although this
study convincingly showed a role for neurogenic
inflammation in TBI, the identification of the
neuropeptide primarily involved in the formation
of increased BBB permeability and edema formation
was not established.
Earlier studies of peripheral edema have shown
that SP is the neuropeptide that is most closely
associated with capsaicin sensitivity (Saria, 1984;
Yonehara et al, 1987). It is also well known that SP is
the neuropeptide responsible for increased vascular
permeability, whereas calcitonin gene-related
peptide is primarily associated with vasodilation.
Finally, Kramer et al (1997) have shown in studies of
cardiac ischemia that SP release is increased with
magnesium depletion; decreases in magnesium con-
centration have been described widely after TBI
(Heath and Vink, 1997; Vink et al, 2003; Cernak et al,
2004). Accordingly, these series of experiments
examined the role of SP in TBI, specifically using
immunohistochemistry to identify increased SP
protein, and an antagonist of the SP neurokinin-1
(NK1) receptor to investigate the role of SP in
increased BBB permeability, edema formation, and
the occurrence of neurologic deficits after TBI.
Materials and methods
All experimental protocols were approved by the Experi-
mental Ethics committees of the University of Adelaide
and the Institute of Medical and Veterinary Science and
were conducted according to guidelines established for the
use of animals in experimental research as outlined by the
Australian National Health and Medical Research Council.
Induction of Traumatic Brain Injury
Injury was induced in halothane-anesthetized male Spra-
gue-Dawley rats (400±20 g) using the acceleration-induced
impact TBI model (Foda and Marmarou, 1994; Cernak et al,
2004). This model involves impacting a 10-mm dia-
meter 3-mm-thick stainless-steel disc fixed centrally to
the exposed skull between the lambda and bregma with an
accelerating impactor. The impactor can either be a 450 g
brass weight dropped from a height of 2 m, or a PC
(personal computer)-controlled, high-velocity impactor.
Earlier studies have shown that both methods of inducing
impact acceleration injury produce similar changes in
axonal injury, edema, BBB opening, Mg2 + decline, and
moderate-to-severe neurologic deficits (Cernak et al, 2004;
Foda and Marmarou, 1994). The weight-drop model
was used in all current experiments with the exception
of magnetic resonance imaging (MRI) experiments, in
which the PC-controlled, high-velocity impactor was used
(velocity, 3.25 m/sec; distance, 18 mm).
All animals were fed and watered ad libitum before the
induction of injury. During surgery, induction of injury,
and during the immediate recovery phase, rat rectal
temperature was maintained at 371C using a thermostati-
cally heated warming blanket. Immediately after injury,
animals were manually ventilated until stable respiration
was restored, usually in < 5 mins. After injury, all wounds
were sutured, animals were withdrawn from anesthesia,
and returned to their cages after recovery.
Drug Treatment
Animals were treated after injury with either the SP NK1
receptor antagonist, N-acetyl-L-tryptophan (NAT) (Towler
et al, 1998), or with an equal volume of saline vehicle. The
dosage of NAT was based on the outcome of the dose-
response curves generated using extravasation of Evans
blue (EB) (Sigma-Aldrich, St Louis, MO, USA) as the
outcome measure, using earlier published dosages (Towler
et al, 1998) as an initial guide to the dose-response curve. A
further subgroup of animals that were either surgically
prepared but not injured (shams) or neither surgically
prepared nor injured (naives) were used as controls, as
appropriate.
Substance P Immunohistochemistry
Animals were injured and perfusion fixed at preselected
time points (n = 5 per group). A further five animals were
used as sham controls. All brains were perfusion fixed
using 4% paraformaldehyde and removed after decapita-
tion. Coronal sections were then cut using a Kopf rodent
brain blocker (Kopf; Tujunga, CA, USA) and the resultant
2-mm sections were embedded in paraffin wax. Serial 5-mm
sections were cut using a microtome (Microm, Walldorf,
Germany) and immunolabeled with SP primary antibody
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(1:2,000 in normal horse serum (NHS); polyclonal cat. no.
SC-9758, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
by overnight incubation at room temperature. After wash-
ing in PBS (phosphate-buffered saline), slices were then
incubated with an anti-goat immunoglobulin G-horserad-
ish peroxidase-conjugated secondary antibody (1:250 in
NHS; Sigma-Aldrich, St Louis, MO, USA) for a minimum
of 30 mins at room temperature. After this, slides were
incubated in the tertiary streptavin peroxidase conjugate
(1:1,000 in NHS; Pierce, Rockford, IL, USA) for at least 1 h
at room temperature, and the subsequent immunocomplex
was visualized using diaminobenzidine tetrahydrochloride
as a chromogen in a peroxidase reaction (Sigma-Aldrich, St
Louis, MO, USA) and examined using a Leica light
microscope (Leica Microsystems, Sydney, NSW, Australia).
Substance P Immunoelectron Microscopy
Animals (n = 3) were injured and decapitated at 5 h after
injury. Floating vibratome sections (100 mm) were then
generated and placed in the PBS buffer (pH 7.4) containing
0.4% Triton X-100 and 1% glycine for 1 h. Blocking of
endogenous peroxidase was achieved by incubation in
methanol containing 0.6% hydrogen peroxide for 30 mins.
The sections underwent antigen retrieval in citrate buffer
(pH6.0) for 2.5 h at 651C, followed by overnight incubation
at room temperature in the primary anti-SP (goat anti-SP
polyclonal antibody, Santa Cruz Biotechnology, N-18,
1:1,000). The sections were then incubated sequentially
with biotinylated mouse anti-goat secondary antibody
(Vector, Burlingame, CA, USA) at a dilution of 1:250 for
60 mins, followed by peroxidase-conjugated streptavidin
(Pierce) at a dilution of 1:1,000 for 60 mins, and developed
with 3,30-diaminobenzidine tetrahydrochloride for 5 mins.
Approximately 4 6 mm pieces containing the cerebral
cortex were cut from the sections, further fixed in 2.5%
glutaraldehyde for 2 h and 1% aqueous osmium for 1 h,
dehydrated with ascending ethanol and propylene oxide,
and embedded in TAAB (TAAB, Aldermaston, Berks,
England) resin. Ultrathin (80 nm) sections were examined
under a transmission electron microscope without any
further staining with either uranyl acetate or lead citrate.
Immunopositive labeled SP appeared as an electron-dense
deposit. Negative control vibratome sections were treated
similarly but with the omission of the primary antibody.
Confocal Microscopy
Paraffin sections of 10-mm thickness from 5-h injured
brains and sham controls (n = 3 per group) were examined
using double immunofluorescent staining with the SP
antibody (Santa Cruz Biotechnology; 1:200 dilution) and
the NK1 receptor antibody (Advanced Targeting Systems,
San Diego, CA, USA; 1:150 dilution). Sections were
incubated overnight in the primary antibodies, then in
the secondary antibodies for 1 h. Secondary antibodies
used were Alexa fluor 488 donkey anti-goat (Molecular
Probes, Eugene, OR, USA; 1:200 dilution) for SP and
Alexa fluor 660 goat anti-rabbit (Molecular Probes; 1:200
dilution) for NK1. After washing in PBS, slides were
mounted using an aqueous mounting solution with anti-
fade and sealed using varnish. Positive and negative
controls were routinely used for all antibodies. Sections
were examined using a confocal fluorescence microscope
(BioRad Radiance 2100, Hemel Hempstead, Hertfordshire,
UK). A subset of animals (n = 3) that were administered EB
dye for the assessment of BBB permeability was also used
for the assessment of SP colocalization with EB.
Enzyme-Linked Immunosorbent Assay
Animals were injured (n = 6 per group) using the impact
acceleration model of TBI as described above. At 30 mins
and 5 h later, injury blood was collected from the tail vein.
The plasma was isolated by centrifugation at 10,000 r.p.m.
(revolutions per minute) for 10 mins and stored at 801C
until use. A further six animals served as uninjured sham
controls. Substance P levels in the plasma were measured
using ELISA (enzyme-linked immunosorbent assay) (R&D
Systems, Minneapolis, MN, USA) according to the manu-
facturer’s instructions. Briefly, plasma was collected in
ethylenediamine tetraacetic acid-lined tubes and diluted in
a ratio of 1:2 in an assay buffer. Samples were then plated
into individual wells on a 96-well plate, and 50 mL of the
SP antibody solution was added. The plates were then
incubated for 2 h at room temperature on a horizontal
orbital microplate shaker (0.12 inch orbit) set at
500±50 r.p.m. The sample wells were than aspirated and
washed thrice with wash buffer before the plate was
inverted and blotted against a clean paper towel. A volume
of 5 mL of SP conjugate was then added, followed by 200 mL
of p-nitrophenyl phosphate substrate, before being incu-
bated for 1 h at room temperature. Addition of stop
solution (R80-0247) after 60 mins permitted the optical
density of each well to be determined using a microplate
reader set at 405 nm with the wavelength correction set
between 570 and 590 nm.
N-acetyl-L-tryptophan Dose Optimization
N-acetyl-L-tryptophan was administered intravenously at
30 mins after TBI at doses ranging between 0.25 and 25 mg/
kg in three steps (n = 6 per group). This range was based on
earlier published work (Towler et al, 1998). The optimal
dose of the NK1 receptor antagonist was determined from
the level of BBB permeability using EB dye extravasation as
the BBB marker (Kaya et al, 2001). Briefly, EB dye (Sigma-
Aldrich cat. no. E-2129; 2 mL/kg of 4%) was administered
intravenously at 4.5 h after impact acceleration induced
TBI and left to equilibrate for 30 mins. At 5 h after TBI,
animals were transcardially perfused with saline to remove
intravascular EB dye and decapitated. After decapitation,
the brain was removed and the cortex was separated and
weighed. Although impact acceleration injury does not
normally result in intraparenchymal hemorrhage (Foda
and Marmarou, 1994; Cernak et al, 2004), brains were
examined routinely during dissection to ensure that no
significant intraparenchymal hemorrhage was present
which could potentially interfere with EB quantitation.
The brain tissue was then homogenized, the protein
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precipitated with trichloroacetic acid, and samples were
cooled for 30 mins and then centrifuged for 30 mins at
1,000 g. The supernatants were measured at 610 nm for
absorbance of EB using a spectrophotometer. Evans blue is
expressed as mg/mg of the brain tissue against a standard
curve.
Edema Determination
The amount of edema development was calculated using
the wet weight–dry weight method. Animals were divided
into three groups (n = 6 per group) and either left uninjured
(sham controls) or treated after injury with NAT, or with an
equal volume of saline vehicle. They were then reanesthe-
tized with 4% halothane at preselected time points and
decapitated. The brain was removed rapidly from the skull,
the olfactory bulbs and the cerebellum were discarded, and
the cortex and subcortex were separated. The cortex and
subcortex of each rat were placed separately into pre-
weighed and labeled glass vials with quick fit lids (to
prevent evaporation) and weighed immediately for wet
water content. The vials (glass lids removed) were then
placed in an oven at 1001C for 72 h. Vials and brain
segments were then reweighed to obtain dry weight
content. Edema in each brain sample was calculated using
the wet–dry method formula:
%Water ¼ ðWet Weight  Dry WeightÞ
Wet Weight
100 ð1Þ
Magnetic Resonance Imaging
At 5 and 24 h after TBI, anesthetized animals (n = 6 per
group) were subjected to MRI examination as described
earlier (Faden et al, 2003; Cernak et al, 2004). Briefly,
animals were placed in the heated plexiglas holder and a
respiratory motion detector was positioned over the thorax
to facilitate respiratory gating. The plexiglas holder was
then positioned in the center of the magnet bore, in which
a 72-mm proton-tuned birdcage coil had been positioned.
Field homogeneity across the brain was then optimized
and sagittal and coronal high-resolution images were
acquired with a multislice–multiecho pulse sequence or a
rapid acquisition relaxation enhancement pulse sequence;
thus, TR (repetition time) = 2 secs, TE (echo time) = 30/
60 msecs, FOV (field of view) = 4 cm, matrix = 512 512,
and slice thickness = 1 mm. Five to seven coronal slices
were obtained per animal, which were positioned precisely
using a sagittal pilot scan and by measuring a known
distance from the anterior pole of the frontal lobe to an
index slice. Multislice, multiecho T2-weighted images
were acquired to obtain eight contiguous slices from the
dorsal end of the olfactory bulb to the rostral margin of the
cerebellum; thus, FOV = 4 4 cm, slice thickness = 2 mm,
resolution 256 256, TR/TE = 2,000/20 msecs, 4 echo
images, and 2 averages. Diffusion-weighted images were
then acquired with a spin echo pulse sequence that had
diffusion gradients added before and after the refocusing
pulse. Gradient strength was varied in six steps using
sensitization values ranging from 20 to 1,000 secs/mm2. A
256 256 matrix was used with a 3-cm FOV, TR = 2.0 secs,
TE = 502 msecs, slice thickness = 2 mm, and 4 echoes.
Diffusion maps were generated by applying the Stejskal–
Tanner equation in association with a Marquart algorithm
using the commercially available Paravision software
(Bruker, Billerica, MA, USA). Apparent diffusion coeffi-
cients (ADCs) were calculated for four regions, namely the
left cortex, right cortex, left subcortex, and right subcortex.
Apparent diffusion coefficients were expressed as
105 mm2/sec±s.e.m.
Functional Outcome
Motor and cognitive outcomes in animals (n = 6 per group)
were assessed using the rotarod and Barnes maze,
respectively, as described in detail elsewhere (O’Connor
et al, 2003). The rotarod device is considered the most
sensitive measure of motor outcome after rodent TBI. It
consists of a motorized rotating assembly of 18 rods (1 mm
in diameter) upon which the animals were placed.
Rotational speed of the device is increased from 0 to
30 r.p.m. and the duration (in seconds) when the animals
either completed the task and fell from the rods or gripped
the rods and spun for two consecutive revolutions rather
than walking actively, was recorded as the rotarod score.
In the Barnes maze, animals were placed under a cover in
the center of an elevated 1.2-m diameter board containing
19 holes around the periphery. One of the holes contained
an entrance to a darkened escape tunnel that is not
visible from the surface of the board. After activating a
series of bright lights aimed at the board and switching
on an aversive auditory stimulus, the cover is lifted and
the latency (in seconds) for the animal to locate and enter
the escape tunnel was recorded. All animals were
pretrained on both functional outcome tests twice per
day over 5 days before injury to establish a normal,
uninjured baseline.
Statistical Analysis
All data are expressed as mean and s.e.m. and, with the
exception of the functional outcome data, were analyzed
for statistical significance using one-way ANOVA (analysis
of variance) followed by Student–Neuman–Keuls tests
(GraphPad Prism Software, La Jolla, CA, USA). Functional
outcome data were analyzed by repeated measures 2-way
ANOVA followed by Student–Neuman–Keuls tests.
Results
Immunohistochemical analysis of tissue after TBI is
shown in Figure 1. The cortex of sham animals
(Figure 1A) shows light SP immunoreactivity along
blood vessels and also within the parenchyma. At 5 h
after injury (Figure 1B), there is an unequivocal
upregulation of SP immunoreactivity along blood
vessels and within the parenchyma. Electron micro-
scopy (Figure 1C) shows that vascular SP immunor-
eactivity is in the adjacent parenchyma
(perivascular) and not within the vessel lumen.
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There was little evidence of SP immunoreactivity in
the vascular endothelial cells. This 5-h time point
has been shown earlier to correlate with the maximal
formation of vasogenic edema and opening of the
BBB (O’Connor et al, 2006). At the level of the
trigeminal tract in sham animals, clear SP immunor-
eactivity could be observed in the tract fibers and to a
lesser extent in the trigeminal nuclei (Figure 1D). At
5 h after injury (Figure 1E), there was a marked
upregulation of SP activity in the trigeminal tract,
nuclei, and in the surrounding tissue.
Given the high level of perivascular SP at 5 h after
TBI, it was of interest to establish whether SP was
detected in the blood after TBI. Accordingly, we used
a competitive ELISA assay to determine SP concen-
tration within plasma samples of injured animals at
30 mins and 5 h after injury. At 30 mins after injury,
there was a significant increase (P < 0.01) in SP
concentration to almost double the basal level
observed in sham animals (Figure 2). These in-
creased levels of SP in the blood declined to sham
levels by 5 h after injury, presumably because of
rapid metabolism by vascular proteases. These
results suggest that SP is released early after TBI, it
is released in the vicinity of the vasculature and
enters the bloodstream, and that this release may be
associated with the early, but transient, opening of
the BBB in this model of TBI.
Figure 1 Substance P (SP) immunoreactivity before and 5 h after diffuse TBI in rats. (A) Minimal SP immunoreactivity (arrowheads)
is noted along blood vessels and within the parenchyma of sham animals (Bar = 100 mm). (B) After injury, increased SP
immunoreactivity along the vessel (center arrowhead) and within the parenchyma (Bar = 100 mm). (C) Electron micrograph showing
that the electron-dense substance P immunoreactivity (arrowheads) noted along blood vessels was perivascular and typically not
associated with vascular endothelial cells (Bar = 5 mm). (D) Low SP immunoreactivity in the brainstem of sham animals can be noted
in the trigeminal tract (T) and in the nuclei (N) (Bar = 100mm). (E) Marked upregulation of SP immunoreactivity in the brainstem
after injury (Bar = 100 mm).
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Having established that SP is increased perivascu-
larly after TBI, we used confocal microscopy to
establish whether there was any association between
SP and a permeability marker, EB, at the level of the
cortical vasculature after TBI. In sham animals, little
SP immunoreactivity can be observed throughout the
section (Figure 3A). However, at 5 h after TBI, there is
clearly a marked increase in perivascular SP im-
munoreactivity such that it delineates the vessels
(Figure 3C). This increase in perivascular SP by
confocal microscopy is consistent with the light
microscopic and electron microscopy results shown
earlier. Colocalization of the SP immunofluorescence
with that of an antibody directed toward the
neurokinin receptor (results not shown) supports
the fact that SP was bound to its NK1 receptor. The
cortical blood vessels with increased SP immunor-
eactivity are clearly permeable at this time point after
TBI as confirmed by the extravasation of the vascular
permeability marker, EB, which was administered
intravenously at 30 mins before tissue removal
(Figure 3D). The short circulation time for EB is
critical so as to ensure that the dye has not diffused
far from the blood vessels. No significant EB was
visible in the sham animals (Figure 3B). Super-
imposition of the images (Figure 3E) shows a
remarkable colocalization of SP with the increased
permeability of the blood vessels as shown by the EB
dye, supporting an association between SP and the
development of increased vascular permeability.
Earlier studies have established that impact accel-
eration injury results in an increased permeability of
the BBB (O’Connor et al, 2006). Having characterized
the vascular colocalization of SP with the NK1
receptors, and given their potential role in increasing
vascular permeability (Nimmo et al, 2004), we
examined the effects of different doses of the NK1
receptor antagonist, NAT, on BBB permeability after
injury (Figure 4). In sham animals, the negligible
penetration of the EB dye confirmed that the BBB
was intact despite induction of anesthesia and
surgery. At 5 h after injury, a significant increase
(P < 0.001) in EB dye was detected indicating
increased BBB permeability. In contrast, NAT treat-
ment resulted in a profound reduction in EB
penetration (P < 0.001), with the optimal dose being
2.5 mg/kg intravenously.
Having established the dose optimum for NAT, its
effects on any edema formation after TBI was
assessed using MRI. Qualitatively, ADC maps de-
rived from diffusion-weighted MRI show relatively
brighter areas of hyperintensity throughout the
brain of vehicle (saline)-treated injured animals
(Figure 5B) compared with that of sham animals
(Figure 5A). This hyperintensity reflects less restric-
tion for water diffusion, consistent with increased
extracellular water, and is unlikely to be because of
the loss of diffusion barriers (membrane breakdown)
given that the images were acquired between 4 and
5 h after injury. Thus, the hyperintensity is thought
to reflect vasogenic edema formation, consistent with
earlier diffusion-weighted image results (Hanstock et
al, 1994; Nimmo et al, 2004). In contrast, animals
treated with the NK1 receptor antagonist at 30 mins
after TBI did not show any hyperintensity through-
out the brain, suggesting an attenuation of edema
formation after injury (Figure 5C). Quantitatively, the
ADC differences are shown in Figure 5D. Sham and
naive animals showed similar mean ADC values in
all regions of the brain (74.8±2.68 and
72.63±1.09 105 mm2/sec, respectively), which is
similar to earlier published results (Albensi et al,
2000; Hanstock et al, 1994). After injury, there was a
significant increase (P < 0.001) in ADC values in
vehicle-treated animals (88.5±2.67 105 mm2/sec)
compared with that in sham-treated animals, con-
firming an increased ADC for water, and consistent
with vasogenic edema formation. This increase was
significantly inhibited (P < 0.001) in the NAT-treated
animals (69±6.7 105 mm2/sec), which were not
significantly different from sham animals.
The changes in edema described using MRI were
confirmed using wet weight–dry weight determina-
tions of brain water content (Figure 6). The percen-
tage of water content in sham animals (77.8±0.2%)
was consistent with those published earlier (Bareyre
et al, 1997; O’Connor et al, 2006). At 5 h after injury,
vehicle-treated animals had a significantly increased
level of brain water content (P < 0.001), indicating the
development of edema after diffuse TBI. Treatment
with NAT at 30 mins after TBI led to a significant
reduction of edema at 5 h after injury (P < 0.001)
compared with vehicle controls. This water content
after NAT treatment was not significantly different
from sham values. These results were consistent
with the MRI data shown above.
Finally, the effects of the NK1 antagonist on
functional outcome were assessed using the rotarod
test for motor function and the Barnes maze for
cognitive outcome (Figure 7). Before the induction of
injury, all animals achieved a mean rotarod score of
Figure 2 Plasma concentration of SP after diffuse TBI as
assessed by ELISA assay (n = 6 per group). **P < 0.001
relative to sham animals.
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111±4 secs. After injury, there was a highly signifi-
cant decrease (P < 0.001) in the rotarod score in
vehicle-treated animals to 23±8 secs at day 1 after
injury (Figure 7A). Thereafter, animals improved
their performance with repeated exposure to the task.
In contrast, animals treated with the NK1 antagonist
at 30 mins after TBI performed significantly better
(P < 0.001) than vehicle-treated controls, recording a
Figure 3 Confocal images of SP and Evans blue (EB) in the rat cortex of sham (uninjured) animals and injured animals at 5 h after
diffuse TBI. (A) Sham animals show little SP immunoreactivity. (C) Increased perivascular SP immunofluorescence after injury clearly
delineates the blood vessels. (B) Sham animals show little EB immunofluorescence. (D) Injured animals show marked EB
immunofluorescence that clearly delineates the blood vessels. (E) Combining the postinjury images shows clear colocalization of
both SP and EB at the level of the cortical vessels, suggesting an association between increased SP and increased vascular
permeability. (Bar = 60 mm).
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minimum value of 82±11 secs at 1 day after injury
and improving thereafter. At no time point were the
NK1-treated animals significantly different from
sham controls. Similarly, in the Barnes cognitive
maze (Figure 7B), animals treated with the NK1
antagonist had significantly reduced cognitive defi-
cits (P < 0.001) compared with vehicle-treated ani-
mals. Again, at no time point was the cognitive
performance of the NK1-treated animals significantly
different from that of sham controls.
Discussion
In this study, we have shown that the neuropeptide
SP is upregulated after TBI, and that administration
of the NK1 receptor antagonist NAT results in the
attenuation of posttraumatic BBB permeability, ede-
ma formation, and neurologic deficits. Before these
results, only one study had earlier implicated
sensory neuropeptides, and in particular SP, in
neurogenic inflammation after TBI. Nimmo et al
(2004) showed that an earlier depletion of neuropep-
tides from sensory nerves led to an inhibition of the
BBB opening, edema formation, free Mg2 + decline,
and to the development of motor and cognitive
deficits after TBI. Before these findings, very few
reports describing the role of neuropeptides in
nervous system injury had been published. Indeed,
only isolated reports in peripheral nerve injury
(Malcangio et al, 2000), traumatic spinal cord injury
(Sharma et al, 1993), and brain ischemia (Stumm
et al, 2001) had described the inflammatory release
of sensory neuropeptides. Of these, only the studies
of brain ischemia showed an activation of neuropep-
tide receptors in the endothelium related to edema
formation (Stumm et al, 2001), similar to what has
been well characterized in peripheral tissue injury
(Woie et al, 1993). The results of our study, in which
TBI-induced development of edema is associated
with increased extravasation of EB across the BBB,
are consistent with these earlier observations that
activation of neuropeptide receptors leads to edema
formation.
The early increase in BBB permeability supports
published findings showing that TBI induces a
maximal increase in permeability within the first 3
to 6 h after injury, along with early edema formation
(O’Connor et al, 2006). This same study described
that the edema formation after injury occurred in two
phases with an early vasogenic episode directly
related to BBB permeability, and a second prolonged
cytotoxic episode occurring over the subsequent
days independent of increased BBB permeability. In
Figure 4 Effects of NAT on brain tissue concentration of Evans
blue at 5 h after diffuse TBI (n = 6/group). A concentration of
2.5 mg/kg was the optimum dosage to reduce EB extravasation.
Figure 5 Effects of NAT treatment on apparent diffusion
coefficients (ADC) after diffuse TBI. Representative ADC maps
are shown for (A) sham animals; (B) injured animals at 5 h after
injury; and (C) injured animals at 4.5 h after NAT treatment.
Areas of hyperintensity indicate the presence of vasogenic
edema. ***P < 0.001.
Figure 6 Percentage cortical water content in male rats 5 h after
diffuse TBI and after treatment with NAT (n = 6 per group).
**P < 0.01 compared with sham levels.
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this study, administration of the NK1 receptor
antagonist 30 mins after TBI attenuated both the
BBB opening and the early vasogenic edema forma-
tion, and supports a direct role for SP in these events.
The role of SP in vasogenic edema was confirmed
using MRI diffusion-weighted imaging, in which
bright areas of hyperintensity throughout the
ADC maps of the injured brain occurred 4 to 5 h
after injury, and a marked reduction occurred
after treatment with the NK1 receptor antagonist.
Quantitation of the brain water content confirmed
the MRI results. This early formation of vasogenic
edema was consistent with earlier published results,
including those of Hanstock et al (1994) who used
the lateral fluid percussion device to show that TBI
results in an increased water diffusion distance with
the directionality indicating bulk flow of extracel-
lular fluid toward the lateral ventricles (vasogenic
edema). Albensi et al (2000) also showed that the
fluid percussion model resulted in regions of
increased ADC early after TBI that may be associated
with vasogenic edema formation. Beaumont et al
(2000) showed that diffuse impact acceleration
induced-injury resulted in vasogenic edema despite
only a very brief BBB opening (Beaumont et al,
2000). Moreover, these authors also showed that the
early vasogenic edema is permissive for the subse-
quent cytotoxic edema, suggesting that the inhibition
of the vasogenic episode may also attenuate subse-
quent cytotoxic edema.
The results of our study also show that SP release
and binding to the NK1 receptor may influence
functional outcome after TBI. The attenuation of
motor deficits with the NK1 receptor antagonist was
shown using the rotarod test, whereas the Barnes
maze was used to show the efficacy on cognitive
outcome. The rotarod test has been described earlier
as the most sensitive test for the detection of motor
deficits after rodent TBI (Hamm, 2001) and both the
rotarod and Barnes maze has been used successfully
in earlier diffuse TBI studies to assess the effects of
pharmacological agents on motor and cognitive
deficits (Heath and Vink, 1997; O’Connor et al,
2003; Vink et al, 2003). The cognitive effects of the
NK1 antagonist may be attributed to the high
numbers of sensory neuropeptide receptors in the
hippocampus and striatum, those parts of the brain
that are known to be associated with learning and
memory. Supporting this role are studies that have
confirmed that alterations in the neuropeptides
calcitonin gene-related peptide, neuropeptide Y,
and SP in the hippocampus are associated with
cognitive deficits as well as with motor function
(Gaumann et al, 1990). A number of other studies
have also shown that the use of a NK1 receptor
antagonist can be beneficial to outcome. Specifically,
Pothoulakis et al (1994) showed that pretreatment
with a NK1 antagonist significantly inhibited the
effects of an inflammatory toxin within the ilium of
rats, whereas Rupniak and Kramer (1999) have
described the efficacy of NK1 antagonists in the
treatment of experimental depression and emesis. A
similar beneficial role for NK1 antagonists has been
suggested by Nimmo et al (2004), who showed that
neuropeptide depletion before induction of TBI
attenuated the development of neurogenic inflam-
mation.
Although the mechanisms by which the NK1
receptor antagonists are neuroprotective are un-
known, there are a number of possibilities whereby
administration could attenuate the actions of SP. A
limited number of studies have identified a potential
role for SP in the glial response to TBI. Receptor
binding sites for SP have been shown to increase on
the glia after neuronal injury (Lin, 1995). As SP is
known to regulate inflammatory and immune re-
sponses in the peripheral tissue, it therefore may
regulate the glial response to injury. Subsequent
studies have confirmed that in response to SP after
injury, astrocytes become ‘reactive’ and mitogenesis
and production of several soluble mediators, such as
cytokines, prostaglandins, and thromboxane deriva-
tives are induced (Marriott et al, 1991; Palma et al,
1997). This increase was not observed in undamaged
areas (Lin, 1995). Moreover, levels of SP have been
shown to increase after traumatic spinal cord injury;
Figure 7 Effects of NAT on neurologic outcome after diffuse TBI in rats as assessed using (A) the rotarod motor test and (B) the
Barnes maze cognitive test (n = 6/group). *** = P < 0.001, * = P < 0.05 versus vehicle.
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these increases have been shown to be inhibited by
serotonin antagonists (Sharma et al, 1990). There are
a number of roles SP may play in the pathophysiol-
ogy of TBI. Substance P induces endothelial cells to
produce nitric oxide (Persson et al, 1991), which has
been implicated as a secondary injury factor. Sub-
stance P also primes polymorphonuclear cells for
oxidative metabolism (superoxide production)
(Hafstrom et al, 1998), thus providing a source of
reactive oxygen species known to exacerbate the
injury process. Weglicki and Phillips (1992) have in
fact postulated that SP release may be one of the
earliest pathophysiological events associated with
injury-induced declines in tissue Mg2 + concentra-
tion, leading to stimulation of the inflammatory
cytokines, which may then stimulate free radical
mechanisms of injury.
Further insight into the possible mechanisms for
SP may be gained from earlier studies using NK1
receptor antagonists in a variety of conditions.
Neurokinin-1 receptor blockade reduces prenecrotic
perivascular inflammatory infiltration, and reducing
circulating histamine, prostaglandin E2 and lipid
peroxidation products (Kramer et al, 1997). Weglicki
and Phillips (1992) have in fact postulated that SP
release may be one of the earliest pathophysiological
events associated with injury-induced declines in
tissue Mg2 + concentration, leading to stimulation of
the inflammatory cytokines, which may then stimu-
late free radical mechanisms of injury. Neurokinin-1
receptor antagonists have also been shown to rapidly
improve mood by antagonizing SP-induced anxiety
(Kramer et al, 1998; Saria, 1999). Thus, they may be
effective in treating posttraumatic depression. The
antagonists also have been shown to inhibit pain
(Saria, 1999), along with being a beneficial treatment
for cerebral ischemia (Yu et al, 1997).
In conclusion, we have shown that inhibition of
neurogenic inflammation by posttraumatic adminis-
tration of the NK1 receptor antagonist NAT inhibits
BBB permeability, vasogenic edema formation, and
improves functional outcome. These results show
sensory neuropeptides, and in particular, SP may
play a significant role in the posttraumatic, second-
ary injury processes and may offer a novel target for
the development of interventional pharmacological
strategies.
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